Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1,968 DKK | +0.14% | -1.82% | -8.52% |
04-30 | Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer | MT |
04-30 | Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.52% | 18.2B | |
-1.17% | 104B | |
+2.87% | 97.47B | |
+3.78% | 22.25B | |
-14.77% | 21.68B | |
-39.98% | 17.02B | |
-13.21% | 16.36B | |
+8.55% | 14.39B | |
+35.75% | 12.37B | |
+310.48% | 8.43B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Genmab A/S : RBC Lifts Price Target on Genmab to $56 From $55 Amid Tivdak US Approval, Potential for Combination Therapy; Outperform Kept